Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology

Bılıcı, Ahmet; Ozturk, Turkan; Türkmen, Esma; Odabaş, Hatice; Cihan, Şener; Selçukbiricik, Fatih; Erdoğan, Bülent; Urakci, Zurat; Kandemir, Nurten; Bayoğlu, İbrahim Vedat; Demirci, Umut; Duran, Ayşe Ocak; Şendur, Mehmet Ali Nahit; Yavuzer, Dilek; Harputluoğlu, Hakan; Kavgacı, Halil; Gümüş, Mahmut

doi:10.1007/s00345-015-1492-9

Cited by 13 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 33% are referred to surveillance regimens and only 5% receive radiotherapy [31]. Noteworthy, radiotherapy is still the most popular treatment for seminoma patients in the United States and in Eastern European countries [28], [32]. However, surveillance and carboplatin are slowly gaining shares [33].…”

Section: Discussionmentioning

confidence: 99%

Seminoma Clinical Stage 1 - Patterns of Care in Germany

et al. 2016

View full text Add to dashboard Cite

Introduction: International guidelines are ambivalent regarding the recommendations for the management of clinical stage 1 (CS1) seminoma. Patients and Methods: During 2008-2013, 1,050 patients with seminoma CS1 were prospectively registered with regard to assessing management modality (radiotherapy, carboplatin, surveillance). Associations with tumor size, rete testis invasion, age, year of diagnosis, type of institution, and geographic location were assessed. Results: Of the total number of patients, 49.3% received carboplatin 1 course, 8.5% carboplatin 2 courses, 35.9% surveillance, and 6.3% radiotherapy. In 2013, surveillance increased significantly to 57.9%. Treatment decisions were significantly associated with rete testis invasion and tumor size. Carboplatin was applied significantly more in office clinics than elsewhere. There is some regional variation regarding treatment preferences. Conclusions: The rising acceptance of surveillance mirrors international trends. The associations with prognostic factors demonstrate care givers to be compliant with contemporary guidelines. The association with the type of institution suggests non-oncological factors to be also relevant in decision making.

show abstract

Section: Discussionmentioning

confidence: 99%

Seminoma Clinical Stage 1 - Patterns of Care in Germany

et al. 2016

View full text Add to dashboard Cite

show abstract

“…3,10,11 Although the significance of these risk factors has been questioned in recent prospective studies, those studies lacked important clinical details in an appreciable fraction of cases. 17 Consequently, current practice has varied, 18,19,20,21 and a recent multicenter study has shown that approximately one quarter of patients with stage I seminoma received adjuvant chemotherapy. 13 In NSGCTs, LVI and/or tumor comprising a > 50% embryonal component are recognized as risk factors for relapse and distant metastasis.…”

Section: Karin Purshouse Et Almentioning

confidence: 99%

Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors

Purshouse

Watson

Church

et al. 2017

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…The irradiation area in testicular seminoma CS I had been reduced from the traditional dog-leg, consisting of para-aortal (PA) and ipsilateral pelvic lymph nodes to the PA area [ 18 , 30 , 31 ].…”

Section: Rules Of Radiotherapy In Gctmentioning

confidence: 99%

“…In the group of 282 patients with seminoma in CS I, treated between 1997 and 2013, reported by Bilici et al ., 130 (46.1%) patients received PORT. During the five-year follow-up, the OS of the AS group was lower when compared with adjuvant treatment patients, but statistical difference was not demonstrated [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy in testicular germ cell tumours – a literature review

Jońska-Gmyrek

Pęczkowski

Michalski

et al. 2017

View full text Add to dashboard Cite

Testicular germ cell tumours (GCT) represent about 1–2% of malignant in men. The essential therapeutic option for early-stage GCT is radical orchiectomy (RO), except in situations that require immediate chemotherapy in patients with a massive dissemination and unequivocally elevated levels of tumour markers.Postoperative radiotherapy (PORT) in patients with testicular seminoma in Clinical Stage I (CS I) is one of the treatment options next to active surveillance (AS) and chemotherapy (CHTH). Regardless of the procedure, five-year survival in this group of patients ranges between 97% and 100%.In the article, we present the literature review pertinent to therapeutic options, with a focus on radiotherapy. We have searched MEDLINE (PubMed) for all studies on patients with GCT treated with radiation therapy during the last 20 years, and the current therapeutic recommendations. We used the following keywords: germ cell tumours, testis, seminoma, non-seminoma, radiotherapy, outcome.

show abstract

Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology

Cited by 13 publications

References 20 publications

Seminoma Clinical Stage 1 - Patterns of Care in Germany

Seminoma Clinical Stage 1 - Patterns of Care in Germany

Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors

Radiotherapy in testicular germ cell tumours – a literature review

Contact Info

Product

Resources

About